We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Moderna Inc | BIT:MRNA | Italy | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.00 | - |
From May 2019 to May 2024
DOW JONES NEWSWIRES
MDRNA Inc. (MRNA) said its technology significantly reduced tumor growth in models of liver and bladder cancer.
Shares jumped 20.2% premarket to $1.49. The stock had nearly quadrupled already in 2009 through Friday.
The biotechnology company, which is focused on the development and commercialization of therapeutic products based on RNA interference, said it successfully demonstrated delivery of a protein that helps shrink tumors. For liver cancer, MDRNA called the reduction similar to what is achieved with Avastin, the billion-dollar seller from Roche Holding AG (RHHBY).
"These data are a powerful indicator of the value and strength of" the RNAi drug discovery platform "and represents a significant step in the advancement of our product pipeline," said President and Chief Executive J. Michael French. "Moreover, we now have evidence illustrating the potential role of RNAi-based therapeutics in down-regulating typically 'non-druggable' targets."
-By Kevin Kingsbury, Dow Jones Newswires; 201-938-2136; kevin.kingsbury@dowjones.com
1 Year Moderna Chart |
1 Month Moderna Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
